A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
Latest Information Update: 02 Sep 2022
At a glance
- Drugs Varenicline (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Acronyms REDUCE TO QUIT
- Sponsors Pfizer
- 30 Mar 2017 Results of Japanese subgroup analysis (n=210) published in the British Journal of Dermatology
- 12 Feb 2014 New trial record
- 21 Jan 2014 Preliminary results published in a Pfizer media release (data subject to additional analyses).